The Ministry of Health and Prevention (MoHAP) in the UAE has withdrawn batch number ME051 of the API Sinocort Nasal Spray, a medication that's used to treat asthma and blocked airways.
The spray is manufactured by Amman Jordan Pharmaceutical Industries.
In a statement, MoHAP said the decision was made after a review of the batch showed it had failed to conform to the approved specifications.
Pharmacists and healthcare providers have been ordered to withdraw it from sale and return the drug to the suppliers
Users are advised to dispose of the batch and report any adverse reactions.
Dr. Amin Hussein Al Amiri, Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, and Chairman of the Supreme National Committee for Pharmacovigilance, urged people to contact them by email at ph@moh.gov.ae, through the E-system on MoHAP’s website, or the smart app ‘UAE RADAR.’
No injuries after debris incident in central Dubai
UAE air forces respond to more missile threats on Friday
UAE air defences intercept 10 ballistic missiles and 26 drones on Thursday
UAE allows residents with expired residency visas to re-enter
Sharjah issues public safety guide for emergencies
UAE and Syrian Presidents stress importance of dialogue, diplomacy
Dubai Health reports 46% rise in kidney transplants
UAE reviews community wellbeing initiatives for Year of Family
